LUME-Lung 1: the addition of Nintedanib to docetaxel
does not adversely effect patients’ self-reported QoL
Trend towards improvements in time-to-deterioration for global health
status/QoL in patients with adenocarcinoma
QLQ-LC13 and QLQ-C30: European Organisation for Research and Treatment of Cancer (EORTC) QoL questionnaires.
Novello S, Eur J Cancer. 2015 Feb;51(3):317–326
Adenocarcinoma
p-value
Cough (QLQ-LC13)
0.4285
Dyspnoea (QLQ-LC13)
Dyspnoea at rest
Dyspnoea after walking
Dyspnoea after climbing stairs
0.9786
0.8015
0.9782
0.6267
Short of breath (QLQ-C30)
Pain (QLQ-C30)
Have pain
Pain affecting daily activities
0.0787
0.0332
0.2080
Pain in chest (QLQ-LC13)
0.0196
Pain in arm and shoulder (QLQ-LC13)
0.0004
Pain in other parts (QLQ-LC13)
0.1136
Favours nintedanib
–20
–15
–10
–5
0
5
Difference in mean score
